Vaishali Pharma (VAISHALI) Q3 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 24/25 earnings summary
20 Nov, 2025Executive summary
Un-audited financial results for the quarter and nine months ended December 31, 2024, were approved by the Board and reviewed by statutory auditors, with no material misstatements identified.
Financial highlights
Revenue from operations for Q3 FY25 was ₹2,791.43 lakhs, nearly flat year-over-year (₹2,789.54 lakhs in Q3 FY24).
Net profit for Q3 FY25 was ₹144.26 lakhs, down from ₹211.19 lakhs in Q3 FY24.
Total income for the nine months ended December 31, 2024, was ₹6,898.12 lakhs, up from ₹5,501.19 lakhs in the prior year period.
Net profit for the nine months was ₹510.99 lakhs, compared to ₹540.14 lakhs for the same period last year.
Basic and diluted EPS for Q3 FY25 stood at ₹1.11, compared to ₹1.99 in Q3 FY24.
Outlook and guidance
Financial statements were prepared in accordance with Indian Accounting Standards and reviewed by the Audit Committee and Board.
Latest events from Vaishali Pharma
- Q1 FY27 net profit rose to ₹148.97 lakh standalone, with consolidation of Kesar Pharma boosting group results.VAISHALI
Q1 26/27 - Strong revenue and profit growth, with new associate consolidation and auditor caution on receivables.VAISHALIQ4 25/26
- Q3 FY26 profit rose sequentially, preferential issue to raise ₹12.25 crore approved.VAISHALIQ3 25/26
- Strong revenue and profit growth with improved margins and positive operating cash flow.VAISHALIQ2 25/26
- Q1 FY26 saw higher revenue but lower net profit and EPS amid rising expenses.VAISHALIQ1 25/26
- Revenue and profit rose, but auditor flagged major uncertainty over receivables' recovery.VAISHALIQ4 24/25
- Revenue and net profit rose year-over-year, with strong equity growth and robust financing inflows.VAISHALIQ2 24/25
- Q1 FY25 saw higher revenue, a return to profit, and increased share capital.VAISHALIQ1 24/25